A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer

Trial Profile

A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Plasminogen (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors ProMetic Biosciences
  • Most Recent Events

    • 04 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 01 Nov 2017 New trial record
    • 26 Oct 2017 According to a ProMetic BioSciences media release, the compnay has received Swedish Medical Products Agency (MPA) Clinical Trial Application (CTA) approval to commence this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top